(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Best and Safe Dividend Stocks to Buy Now. Bristol-Myers ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

Bristol Myers Squibb (BMY) and Bain Capital have announced the formation of a new independent biopharmaceutical company dedicated to developing innovative therapies for ...

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

Bristol Myers Squibb's first-half non- GAAP diluted earnings per share (EPS) advanced 9.6% year over year to $3.67, which is impressive growth. Upcoming blockbuster brands and an enviable pipeline ...

Bristol Myers Squibb's first-half revenue advanced 8.9% year over year to $22.8 billion, which was driven by solid growth from its top three drugs -- Revlimid, Eliquis, and Opdivo.

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...